SP Funds S&P World ex-US ETF(SPWO.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
SP Funds S&P World ex-US ETF
SPWO.US
News
View More

Syngenta Adopts SAP AI Solutions To Boost Farming Efficiency

Syngenta has partnered with SAP to integrate AI across its operations, modernizing processes with SAP Cloud ERP to enhance efficiency and innovation in agriculture. The partnership aims to support global agricultural growth and improve decision-making through advanced data analytics. SAP's stock is currently in a bearish trend, trading below key moving averages, with a recent decline of 8.75% over the past year. Traders should monitor key support and resistance levels as the stock shows signs of potential upward movement.

benzinga_article·
US
SAP
-0.95%
benzinga_article·
US
SAP
-0.95%

BGI Genomics, Roche roll out diagnostic tests for Alzheimer's in China

BGI Genomics and Roche Diagnostics have launched Alzheimer's diagnostic tests in China to improve access to easier diagnosis and monitoring. BGI's blood test is being used in several cities to assess disease progression, while Roche is working on a test for pTau181 in Boao. These blood tests aim to expedite diagnosis and facilitate access to treatments, contrasting with traditional methods like spinal taps and PET scans. Both companies emphasize that their tests are not standalone diagnostic tools but can aid in early screening and reduce unnecessary investigations.

Reuters·
SZ
300676
-6.85%
US
RHHBY
+0.24%
Reuters·
SZ
300676
-6.85%
US
RHHBY
+0.24%

AZ's $80B revenue target 'very much within reach,' CFO says

AstraZeneca's CFO Aradhana Sarin stated at the J.P. Morgan Healthcare Conference that the company's $80 billion revenue target for 2030 is achievable, especially if they maintain last year's success in phase 3 trials. The oncology portfolio has seen significant growth, with 10 positive phase 3 readouts last year and an increase in late-stage drug opportunities. Analysts' projections for 2030 have risen to match the target. Key products include Imfinzi and Tagrisso, with ongoing trials expected to enhance their market positions. AstraZeneca is also focusing on cardiovascular drugs and navigating drug pricing regulations.

Fiercepharma·
US
AZN
+0.43%
Fiercepharma·
US
AZN
+0.43%

AstraZeneca to acquire Modella AI to speed oncology drug research

AstraZeneca has agreed to acquire Modella AI to enhance its oncology drug research using artificial intelligence. The financial terms were not disclosed. Modella AI's technology will support clinical development and biomarker discovery, addressing the complexities of oncology drug development. This acquisition marks the first by a major pharmaceutical company in the AI sector. AstraZeneca aims to integrate AI capabilities to improve patient selection for drug trials, potentially increasing clinical success rates and reducing costs. The deal follows a previous collaboration between the two companies.

Reuters·
UK
AZN
0.00%
US
AZN
+0.43%
Reuters·
UK
AZN
0.00%
US
AZN
+0.43%

JPM26: Novartis strengthens neuroscience portfolio with bolt-on deals

At the J.P. Morgan Healthcare Conference 2026, Novartis announced its strategy to enhance its neuroscience portfolio through mergers, acquisitions, and licensing deals. The $12bn acquisition of Avidity Biosciences is set to close in H1 2026, adding significant assets to its neuromuscular portfolio. Additionally, a licensing agreement with SciNeuro for an Alzheimer’s treatment was revealed, alongside a collaboration with Arrowhead for a Parkinson’s therapy. Novartis aims to strengthen its pipeline in neuromuscular and neurodegenerative diseases, positioning neuroscience as a key revenue driver.

Pharmaceutical Technology·
US
RNA
-0.12%
US
NVS
+0.83%
Pharmaceutical Technology·
US
RNA
-0.12%
US
NVS
+0.83%
© 2026 Longbridge｜Disclaimer